Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In vivo biological standardization of Olea europaea allergen extracts
2025-523866-26-00Phase 2Authorised
- Sponsor
- Asacpharma
- Start
- Feb 2026
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olea europaea pollen extract in olive pollen allergy, sponsored by Asacpharma. Primary endpoints: Skin wheal area to Olea europaea extracts, Dose-response relationship of Olea europaea extracts and 1 more. Planned start Feb 2026; status: authorised.
02
Drugs
olea europaea pollen extract
03
Conditions
olive pollen allergy
Beyond the preview
Go deeper on 2025-523866-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523866-26-00.